…
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hepatocellular carcinoma (HCC), metabolic liver diseases, and chronic liver diseases in the United States. It developed Rencofilstat, a therapeutic drug candidate that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulates protein folding, as well as preclinical experiments of Rencofilstat reflects decreased liver fibrosis; liver inflammation; liver tumor burden; and titers of HBV, HCV, and HDV. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Morristown, New Jersey.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Hepion Pharmaceuticals is a clinical-stage biopharma developing therapies for chronic liver diseases; its lead candidate CRV431 is a cyclophilin inhibitor being developed for NASH, liver fibrosis and related indications. Long-term drivers include clinical progress, potential approvals or partnerships, and the large unmet need for NASH and antifibrotic treatments; investors may view the differentiated mechanism and multi-indication potential as attractive.
Key risks are clinical or regulatory failure, limited cash runway requiring additional financing, and significant competition and scientific uncertainty in NASH and liver therapeutics.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -8.28M | -16.16M | -49.34M | -45.08M | -32.72M |
| Net income | -8.28M | -13.19M | -48.93M | -42.20M | -32.72M |
| Selling general administrative | 3.32M | 7.50M | 9.62M | 10.35M | 10.01M |
| Selling and marketing expenses | - | - | 0.07M | - | - |
| Gross profit | - | -0.03M | -0.07M | -0.08M | -0.09M |
| Reconciled depreciation | 0.00M | 0.03M | 0.07M | 0.08M | 0.09M |
| Ebit | -3.76M | -14.91M | -45.26M | -43.62M | -30.40M |
| Ebitda | -3.73M | -14.88M | -45.19M | -43.54M | -30.32M |
| Depreciation and amortization | 0.03M | 0.03M | 0.07M | 0.08M | 0.09M |
| Operating income | -4.16M | -19.35M | -45.26M | -45.49M | -30.40M |
| Other operating expenses | 4.16M | 19.35M | 45.26M | 43.62M | 30.40M |
| Interest expense | 0.02M | 1.25M | 0.01M | 0.01M | 0.01M |
| Tax provision | 0.00M | -2.97M | -2.88M | -2.88M | -0.00M |
| Net interest income | -0.02M | -1.25M | -0.01M | -0.01M | -0.01M |
| Non recurring | - | - | - | 1.87M | - |
| Income tax expense | - | -2.97M | -0.41M | -2.88M | 0.01M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 4.16M | 19.35M | 45.19M | 43.62M | 30.40M |
| Cost of revenue | - | 0.03M | 0.07M | 0.08M | 0.09M |
| Total other income expense net | -4.11M | 3.18M | -4.08M | -1.46M | -2.31M |
| Net income from continuing ops | -8.28M | -13.19M | -44.68M | -42.20M | -32.72M |
| Net income applicable to common shares | - | - | - | -45.34M | -32.72M |
| Preferred stock and other adjustments | - | - | - | 3.14M | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 3.07M | 1.61M | 18.09M | 60.24M | 103.55M |
| Intangible assets | - | - | - | 3.19M | 3.19M |
| Other current assets | 1.24M | 1.21M | 2.70M | 5.31M | 6.10M |
| Total liab | 0.40M | 3.48M | 10.81M | 10.39M | 10.56M |
| Total stockholder equity | 2.67M | -1.86M | 7.28M | 49.86M | 93.00M |
| Deferred long term liab | - | - | - | 0.41M | - |
| Other current liab | 0.08M | 0.02M | 0.39M | 5.17M | 2.99M |
| Common stock | 0.00M | 0.00M | 0.00M | 0.01M | 0.01M |
| Capital stock | 1.70M | 1.70M | 1.70M | 1.70M | 1.71M |
| Retained earnings | -246.10M | -237.82M | -224.63M | -175.70M | -133.50M |
| Other liab | - | - | - | 2.50M | 2.30M |
| Good will | - | - | - | 0.00M | 1.87M |
| Other assets | - | - | - | 0.43M | 0.58M |
| Cash | 1.83M | 0.41M | 14.79M | 51.19M | 91.35M |
| Total current liabilities | 0.30M | 3.14M | 5.29M | 7.89M | 8.21M |
| Current deferred revenue | - | - | 2.44M | - | 2.51M |
| Net debt | -1.77M | 2.49M | -14.58M | -51.14M | -91.03M |
| Short term debt | 0.05M | 2.90M | 0.12M | 0.05M | 0.27M |
| Short long term debt | 0.05M | 2.90M | - | - | - |
| Short long term debt total | 0.05M | 2.90M | 0.21M | 0.05M | 0.32M |
| Other stockholder equity | 247.06M | 234.25M | 230.29M | 223.94M | 224.79M |
| Property plant equipment | - | - | - | 0.08M | 0.46M |
| Total current assets | 3.07M | 1.61M | 17.49M | 56.50M | 97.45M |
| Net tangible assets | - | - | - | 44.97M | 86.23M |
| Accounts payable | 0.17M | 0.22M | 2.35M | 2.67M | 2.45M |
| Accumulated other comprehensive income | 0.01M | 0.01M | -0.08M | -0.09M | - |
| Common stock total equity | - | - | - | 0.01M | - |
| Preferred stock total equity | - | - | - | 1.70M | - |
| Retained earnings total equity | - | - | - | -175.70M | - |
| Non currrent assets other | - | 0.00M | 0.30M | 0.43M | 0.58M |
| Non current assets total | 0.00M | 0.61M | 0.61M | 3.75M | 6.10M |
| Capital lease obligations | - | 0.00M | 0.21M | 0.05M | 0.32M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -0.13M | -0.60M | -0.03M | -0.01M | -0.13M |
| Change to liabilities | - | - | - | 2.25M | -1.07M |
| Total cashflows from investing activities | -0.13M | -0.60M | - | -0.01M | -0.13M |
| Net borrowings | -3.37M | 0.00M | - | - | -0.18M |
| Total cash from financing activities | 4.83M | 4.35M | 4.49M | -5.14M | 81.98M |
| Change to operating activities | - | - | - | 0.91M | -4.50M |
| Net income | -8.28M | -13.19M | -48.93M | -42.20M | -32.72M |
| Change in cash | 1.42M | -14.38M | -36.40M | -40.16M | 50.62M |
| Begin period cash flow | 0.41M | 14.79M | 51.19M | 91.35M | 40.73M |
| End period cash flow | 1.83M | 0.41M | 14.79M | 51.19M | 91.35M |
| Total cash from operating activities | -3.27M | -18.22M | -40.89M | -34.96M | -31.22M |
| Issuance of capital stock | 0.00M | 2.50M | 0.00M | 17.86M | 82.15M |
| Depreciation | 0.00M | 0.03M | 0.07M | 0.08M | 0.09M |
| Other cashflows from investing activities | - | -0.60M | - | 0.00M | - |
| Dividends paid | - | - | 0.00M | 0.01M | 0.01M |
| Sale purchase of stock | - | - | 0.00M | -21.00M | 0.18M |
| Other cashflows from financing activities | -0.80M | 1.85M | 0.00M | -2.00M | -0.17M |
| Change to netincome | - | - | - | 4.01M | 6.98M |
| Capital expenditures | 0.00M | 0.01M | 0.01M | 0.02M | 0.13M |
| Cash flows other operating | - | - | - | 0.91M | - |
| Cash and cash equivalents changes | - | - | - | -40.11M | - |
| Change in working capital | 0.49M | -2.68M | 2.97M | 3.15M | -5.57M |
| Stock based compensation | 0.02M | 0.79M | 1.34M | 2.55M | 4.67M |
| Other non cash items | 4.49M | -3.16M | 4.07M | 1.46M | 2.31M |
| Free cash flow | -3.27M | -18.22M | -40.90M | -34.98M | -31.35M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| HEPA Hepion Pharmaceuticals Inc |
-0.04 25.00% |
0.10 | - | - | - | 41.86 | 1.16 |
| NVO Novo Nordisk A/S |
0.98 2.41% |
41.63 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-4.02 0.74% |
538.60 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
4.28 0.45% |
955.47 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
64.70 7.19% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hepatocellular carcinoma (HCC), metabolic liver diseases, and chronic liver diseases in the United States. It developed Rencofilstat, a therapeutic drug candidate that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulates protein folding, as well as preclinical experiments of Rencofilstat reflects decreased liver fibrosis; liver inflammation; liver tumor burden; and titers of HBV, HCV, and HDV. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Morristown, New Jersey.
| Name | Title | Year Born |
|---|---|---|
| Dr. Robert T. Foster B.Sc., BSc (Pharm), Ph.D., Pharm.D. | Pres, CEO & Director | 1958 |
| Mr. John T. Cavan | Chief Financial Officer | 1958 |
| Dr. Todd M. Hobbs M.D. | Chief Medical Officer | 1969 |
| Dr. Launa J. Aspeslet Ph.D. | Chief Operating Officer | NA |
| Dr. Daren Ure Ph.D. | Chief Scientific Officer | NA |
| Sharen Pyatetskaya | Director of Investor Relations | NA |
| Dr. Daniel J. Trepanier Ph.D. | Sr. VP of Drug Devel. | NA |
| Dr. Patrick R. Mayo Ph.D. | Sr. VP of Clinical Pharmacology | NA |
| Dr. John Z. Sullivan-Bolyai | Part-Time Consultant | 1948 |
| Dr. Stephen A. Harrison M.D. | Member of Scientific Advisory Board & Consultant Medical Director | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.